XTL Biopharmaceuticals to Present at the
Jefferies Life Sciences Conference
New York, NY, June 26, 2006 - XTL Biopharmaceuticals, Ltd. (Nasdaq: XTLB, LSE:
XTL;TASE:XTL)announced today that Ron Bentsur, the Company's Chief Executive
Officer, is scheduled to present at the Jefferies Life Sciences Conference. Mr.
Bentsur's presentation will take place on Wednesday, June 28, 2006 at 10:45 am
EDT at The Mandarin Oriental Hotel in New York City.
A live audio webcast of Mr. Bentsur's presentation will be available at
An archived version of the webcast will be available following the conclusion
of the live presentation.
About XTL Biopharmaceuticals, Ltd.
XTL Biopharmaceuticals Ltd. ("XTLbio") is engaged in the acquisition,
development and commercialization of therapeutics for the treatment of
infectious diseases, with a focus on hepatitis C. XTLbio is developing XTL-2125
- a small molecule, non-nucleoside inhibitor of the hepatitis C virus
polymerase. XTL-2125 is currently in a Phase 1 clinical trial in chronic
hepatitis C patients. XTLbio is also developing XTL-6865 - a combination of two
monoclonal antibodies against the hepatitis C virus - presently in Phase 1
clinical trials in patients with chronic hepatitis C. XTLbio's hepatitis C
pipeline also includes several families of pre-clinical hepatitis C small
molecule inhibitors. In addition, XTLbio has out-licensed to Cubist
Pharmaceuticals an antibody therapeutic against hepatitis B, HepeX-B, which has
recently completed a Phase 2b clinical study in hepatitis B liver transplant
patients. XTLbio is publicly traded on the NASDAQ, London, and Tel-Aviv Stock
Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).
Chief Executive Officer